Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05273554 · ClinicalTrials.gov registry record · Phase 1

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

A Phase 1 study of Adenocarcinoma and Tumor, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT05273554 is a Phase 1 study of Adenocarcinoma and Tumor that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants, below the 96-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05273554, a Phase 1 study of Adenocarcinoma and Tumor, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This is a clinical research study to learn if pembrolizumab in combination with lenvatinib can help to control pancreatic ductal adenocarcinoma.

Conditions Studied

Adenocarcinoma Tumor

Interventions

  • DRUG Pembrolizumab
  • DRUG lenvatinib

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2022-08-31
Est. Completion 2027-12-31
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05273554

The ClinicalTrials.gov registry entry for NCT05273554 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 26 other Adenocarcinoma trials with a reported enrollment target (84% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT05273554 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05273554 about?

NCT05273554 is a clinical study titled "A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma". This is a clinical research study to learn if pembrolizumab in combination with lenvatinib can help to control pancreatic ductal adenocarcinoma.

What is the current status of trial NCT05273554?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-08-31. Estimated completion is 2027-12-31.

What conditions does trial NCT05273554 study?

This clinical trial studies the following conditions: Adenocarcinoma, Tumor.

What interventions are being tested in trial NCT05273554?

The interventions under investigation include: Pembrolizumab (DRUG), lenvatinib (DRUG).

Who is sponsoring clinical trial NCT05273554?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05273554 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Adenocarcinoma

All registered trials for this condition

Tumor

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.